765 related articles for article (PubMed ID: 2896559)
1. Comparison of famotidine with cimetidine and ranitidine.
Berardi RR; Tankanow RM; Nostrant TT
Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
[TBL] [Abstract][Full Text] [Related]
2. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
[TBL] [Abstract][Full Text] [Related]
3. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
Campoli-Richards DM; Clissold SP
Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
[TBL] [Abstract][Full Text] [Related]
4. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
Langtry HD; Grant SM; Goa KL
Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of H2-receptor antagonists: an overview.
Schunack W
J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
[TBL] [Abstract][Full Text] [Related]
6. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
[TBL] [Abstract][Full Text] [Related]
7. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
Ohsawa T; Hirata W; Higichi S
Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.
Thomson AB; Mahachai V
Clin Invest Med; 1987 May; 10(3):152-70. PubMed ID: 2887321
[TBL] [Abstract][Full Text] [Related]
9. Clinical importance of the new H2-antagonists.
Walt RP
Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():97-9. PubMed ID: 2566730
[TBL] [Abstract][Full Text] [Related]
10. Famotidine: effective treatment of Zollinger-Ellison syndrome.
Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
[TBL] [Abstract][Full Text] [Related]
11. Famotidine in the therapy of gastric hypersecretory states.
Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
[TBL] [Abstract][Full Text] [Related]
12. Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.
Savarino V; Mela GS; Scalabrini P; Sumberaz A; Fera G; Zentilin P; Celle G
Am J Gastroenterol; 1988 Sep; 83(9):917-22. PubMed ID: 2901220
[TBL] [Abstract][Full Text] [Related]
13. Clinical review of histamine2 receptor antagonists.
Lipsy RJ; Fennerty B; Fagan TC
Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
[TBL] [Abstract][Full Text] [Related]
14. Famotidine in the treatment of duodenal ulcers resistant to other histamine H2-receptor antagonists.
Chen PH; Wang TH; Wang CY; Chen CY; Cheng TC; Tsai YT; Siauw CP; Yang KC; Chen GH; Sung JL
J Int Med Res; 1989; 17 Suppl 1():25A-31A. PubMed ID: 2566541
[TBL] [Abstract][Full Text] [Related]
15. Famotidine in the USA: a review of efficacy studies.
Gitnick G
J Int Med Res; 1989; 17 Suppl 1():17A-24A. PubMed ID: 2566539
[TBL] [Abstract][Full Text] [Related]
16. Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
Bianchi Porro G
Digestion; 1985; 32 Suppl 1():62-9. PubMed ID: 2866137
[TBL] [Abstract][Full Text] [Related]
17. Effects of prolonged oral cimetidine, ranitidine, and famotidine therapy on antipyrine elimination.
Sakaue H; Akamatsu K; Hirabayashi Y; Sasaki T; Nakanishi K; Okada S; Kanaoka M; Nishinobu M; Masumoto S; Ohta Y
Clin Ther; 1987; 9(6):602-6. PubMed ID: 2894244
[TBL] [Abstract][Full Text] [Related]
18. Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine.
Scarpignato C; Tramacere R; Zappia L
Br J Pharmacol; 1987 Sep; 92(1):153-9. PubMed ID: 2889492
[TBL] [Abstract][Full Text] [Related]
19. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
[TBL] [Abstract][Full Text] [Related]
20. Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing.
Khasawneh SM; Affarah HB
Am J Gastroenterol; 1992 Sep; 87(9):1180-2. PubMed ID: 1519576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
